Tau2
Phase 2Small molecule
Tau2 is one of 3 small molecule programs targeting Preclinical Alzheimer's Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Preclinical Alzheimer's Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 2
Aadvac1
AAxon Neuroscience SE
Phase 2
Tau2
PPaul S. Aisen
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tau2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPaul S. Aisen